Navigation Links
Convoy Therapeutics to Present at 2013 Rocky Mountain Life Science Investor and Partnering Conference

Oro Valley, AZ (PRWEB) August 27, 2013

Convoy Therapeutics, Inc. has been selected to present at the 2013 Rocky Mountain Life Science Investor and Partnering Conference. The conference will take place on September 18-19, 2013 in Denver, Colorado and is hosted by the Colorado BioScience Association. Convoy Therapeutics is one company among a field of just thirty from Colorado, Arizona, Utah, Montana, and New Mexico that was chosen to present.

Convoy Therapeutics is a subsidiary of ACTUS Biotechnologies, Inc., an accelerator focused on development of novel technologies into commercially available therapies. The Convoy Therapeutics platform technology is based upon a family of peptides, including the proprietary "SPACE" (Skin Penetrating and Cell Entering) peptide. Studies using the peptide in topical formulations with and without covalent attachment have demonstrated an exceptional ability to deliver molecules as large as 1.6 megadaltons past the stratum corneum and into the deeper layers of the skin. Additionally, the technology is capable of creating reservoirs of small molecules, enhancing retention and decreasing dosing frequency, and a demonstrated ability to enhance the penetration of nucleic acids into the skin and cells.

The Convoy Therapeutics platform technology has an enormous range of potential applications in the pharmaceutical, medical aesthetic, cosmetic and vaccine industries, including the opportunity to transform current oral and intravenous drugs into topical formulations for the treatment of dermatological and other diseases.

The company’s lead programs include a topical cosmetic Hyaluronic Acid product for the reduction of fine lines and wrinkles for use between filler or toxin injections, and CycloPsorb™, a topical cyclosporine prescription product for the treatment of psoriasis. The platform is also being investigated with a number of pharmaceutical and cosmetic partners for use with a variety of large and small molecules. Given the challenge that topical macromolecule delivery has posed to the pharmaceutical industry for so many years, the results of the Convoy Therapeutics platform have been remarkable.

For more information on Convoy Therapeutics, visit the company’s website here. For information on ACTUS Biotechnologies, visit the company’s website here. Additional information on the Rocky Mountain Life Science Investor and Partnering Conference can be found here.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Convoy Therapeutics Announces the Relaunch of Their Interactive Website
2. Orexigen Therapeutics Prepares for the Light Study Interim Analysis Based on Direction from Data Monitoring Committee
3. Technical Study: Vertex Pharma Inc., Orexigen Therapeutics Inc., MAKO Surgical Corp., and Alere Inc.
4. AML Therapeutics Market in the 6MM Worth $430.7m in 2017 Says a New Research Report Available at
5. Global Lung Cancer Therapeutics Market 2013 Report Featuring Leading Players Such As AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Co., GlaxoSmithKline, Hoffmann-La Roche, Novartis And Others
6. Oncology Therapeutics Market in India to 2018 Report
7. PTC Therapeutics Announces Achievement Of Major Milestone In SMA Collaboration
8. NuMe Health Becomes MicroBiome Therapeutics And Recruits New CEO
9. Enteris BioPharma Initiates Business and Development Activities Targeting Oral Delivery of Peptides and Small Molecule Therapeutics
10. Sorrento Therapeutics Announces Reverse Split of Common Stock
11. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Trius Therapeutics, Inc. - TSRX
Post Your Comments:
(Date:11/30/2015)... Nov. 30, 2015  Northwest Biotherapeutics (NASDAQ: NWBO ... personalized immune therapies for solid tumor cancers, announced today ... independent director, and the Company welcomes Neil Woodford,s ... a recent anonymous internet report on NW Bio.  The ... Linda Powers stated, "We agree with Mr. ...
(Date:11/27/2015)... ... November 27, 2015 , ... Pittcon is pleased to ... presentations offered in symposia, oral sessions, workshops, awards, and posters. The core ... of applications such as, but not limited to, biotechnology, biomedical, drug discovery, environmental, ...
(Date:11/25/2015)... 2015  PharmAthene, Inc. (NYSE MKT: PIP) announced  today ... rights plan (Rights Plan) in an effort to preserve ... under Section 382 of the Internal Revenue Code (Code). ... use of its NOLs could be substantially limited if ... Section 382 of the Code. In general, an ownership ...
(Date:11/25/2015)... QUEBEC CITY , Nov. 25, 2015 /PRNewswire/ ... "Company"), affirms that its business and prospects remain ... , Zoptrex™ (zoptarelin doxorubicin) recently received DSMB ... program to completion following review of the final ... met Phase 2 Primary Endpoint in men with ...
Breaking Biology Technology:
(Date:11/9/2015)... 2015 ... "Global Law Enforcement Biometrics Market 2015-2019" ... ) has announced the addition ... Market 2015-2019" report to their offering. ... ) has announced the addition of ...
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has ... to provide preclinical development services to the National Cancer ... SRI will provide scientific expertise, modern testing and support ... of preclinical pharmacology and toxicology studies to evaluate potential ... --> The PREVENT Cancer Drug Development Program is ...
(Date:10/29/2015)... , Oct. 29, 2015 Daon, a global ... it has released a new version of its ... North America have already installed ... also includes a FIDO UAF certified server component ... preparing to activate FIDO features. These customers include some ...
Breaking Biology News(10 mins):